Viridian Therapeutics, Inc.\DE
Viridian Therapeutics is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and rare diseases. Its pipeline centers on antibody and protein therapeutics for autoimmune and rare disease pathways, including thyroid eye disease and other immune-mediated conditions, with development, manufacturing, and future commercialization capabilities built around those programs.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical-stage antibody candidates directed at IGF-1R for thyroid eye disease.
Programs targeting the neonatal Fc receptor for multiple autoimmune disorders.
Research and development program for TED and Graves' disease.
Upfront fees, milestones, royalties, and research support from partners.
Products
Reported · share of revenue- License98.9 %
- Collaboration1.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Viridian does not sell to end consumers in the traditional sense; its economic counterparties are patients, physicians, payors, and healthcare systems that would use or reimburse approved therapies. During development, its direct customers are collaboration partners and licensees that pay for rights, development support, manufacturing services, and milestones. If approved, the commercial customer base would be specialty prescribers and payors in rare-disease and autoimmune markets.
Patients with thyroid eye disease and the specialists who would prescribe veligrotug or elegrobart if approved.
Patients with FcRn-mediated autoimmune disorders targeted by the FcRn inhibitor portfolio.
Biopharma partners that pay upfront fees, milestones, royalties, or service fees under collaboration agreements.
Commercial stakeholders that influence adoption through coverage, access, and utilization management.
Strategy
Viridian’s strategy is to build differentiated, best-in-class therapies for serious and rare diseases where current treatments leave room for better efficacy, safety, or dosing convenience. It is prioritizing TED and autoimmune programs, while also building the commercial, medical, regulatory, and supply-chain infrastructure needed to launch its first approved product and support future products.
TED is the company’s most advanced commercial opportunity and anchors the near-term pipeline.
A successful launch requires sales, access, patient support, and distribution capabilities.
Additional autoimmune programs can diversify the platform and extend the company’s value creation window.
Collaborations can fund development and extend geographic reach without full internal commercialization.
Geography
Viridian is headquartered in Waltham, Massachusetts and operates as a U.S.-based development-stage biopharma company. Its commercialization rights for veligrotug and elegrobart exclude Japan and the greater China region, while collaboration activity includes licensed rights in greater China through partners. As a result, the company’s business is concentrated in the United States but has selective international exposure through licensing and future commercialization rights.
Risks
Viridian faces the typical risks of a clinical-stage biopharma company: uncertain trial outcomes, regulatory approval risk, and the possibility that product candidates never reach market. Its TED programs also face competition from approved and in-development therapies, while combination-product design, manufacturing complexity, and reliance on third-party suppliers can delay development or commercialization.
- Clinical development failureImpact: CriticalLikelihood: Medium
The company’s value depends on positive data from late-stage and early-stage programs.
Exposure - Regulatory and combination-product complexityImpact: HighLikelihood: Medium
Some candidates are or may be combination products requiring coordinated device and drug review.
Exposure - Manufacturing and supply-chain dependenceImpact: HighLikelihood: Medium
The company relies on third parties and single suppliers for development and production.
Exposure - Competitive pressure in TEDImpact: HighLikelihood: Medium
Existing approved therapy and multiple clinical programs could limit market share and pricing.
Exposure: thyroid eye disease market
- Product liabilityImpact: HighLikelihood: Medium
Serious adverse events in rare disease populations can trigger litigation and regulatory setbacks.
Exposure: clinical trials and future commercialization
Accounting
Judgemental itemsRevenue depends on when performance obligations are satisfied and milestones are achieved.
Impact: Can create lumpy quarterly results
The DRI arrangement is treated as debt financing because of continuing involvement.
Impact: Affects leverage presentation and cash flow interpretation
Clinical, CMC, and manufacturing costs are expensed as incurred unless specific criteria are met.
Impact: Directly affects operating loss and comparability across periods
Acquired rights and collaboration assets may require fair-value estimates and impairment testing.
Impact: Can affect intangible asset carrying values and future expense recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
Vor Biopharma Inc.
VOR · Biological Products, (No Diagnostic Substances)
Eledon Pharmaceuticals, Inc.
ELDN · Pharmaceutical Preparations
Cartesian Therapeutics, Inc.
RNAC · Pharmaceutical Preparations
Viking Therapeutics, Inc.
VKTX · Pharmaceutical Preparations
Viking Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders.
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Cullinan Therapeutics, Inc.
CGEM · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026